Capricor Therapeutics Inc (NASDAQ:CAPR) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price target of $6.50 for the company and are anticipating that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also given Capricor Therapeutics an industry rank of 185 out of 265 based on the ratings given to its competitors.
CAPR has been the subject of a number of research reports. HC Wainwright raised their price target on shares of Capricor Therapeutics from $2.15 to $6.50 and gave the stock a “buy” rating in a research report on Friday, September 15th. Zacks Investment Research raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, August 16th. Finally, ValuEngine raised shares of Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd.
Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $1.00 million. The business’s revenue was down 58.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.29) EPS. analysts predict that Capricor Therapeutics will post -0.7 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. LLBH Private Wealth Management LLC increased its stake in shares of Capricor Therapeutics by 27.7% in the 2nd quarter. LLBH Private Wealth Management LLC now owns 184,591 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 40,000 shares in the last quarter. Virtu KCG Holdings LLC increased its stake in shares of Capricor Therapeutics by 571.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 152,614 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $249,000. Jane Street Group LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $190,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $107,000. Hedge funds and other institutional investors own 4.56% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Set $6.50 Target Price for Capricor Therapeutics Inc (CAPR)” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/12/08/zacks-analysts-set-6-50-target-price-for-capricor-therapeutics-inc-capr.html.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.